Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine Phase-III-Studie zu Eque-cel bei Patienten mit Len-refraktärem RRMM (FUMANBA-03) (FUMANBA-03)

3. November 2026 aktualisiert von: Nanjing IASO Biotechnology Co., Ltd.

Eine randomisierte, kontrollierte Phase-III-Studie zur Injektion von Equecabtagene-Autoleucel bei Patienten mit Lenalidomid-refraktärem R/R-Multiplem Myelom

This is a multicenter, randomized, controlled, open-label, phase III clinical study to evaluate the efficacy of Equecabtagene Autoleucel Injection versus standard therapy in subjects with lenalidomide-refractory relapsed/refractory multiple myeloma (RRMM) who have received 1-2 lines of prior therapy. Approximately 240 subjects from China and, in accordance with Japanese regulatory requirements, approximately 20 additional subjects from Japan are planned to be enrolled in this study, for a total of approximately 260 subjects.

Studienübersicht

Status

Aktiv, nicht rekrutierend

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Multiple myeloma (MM) is a malignant neoplasm of plasma cells that accounts for more than 10%-20% of hematologic malignancies worldwide, leading to marrow failure and bone destruction. Equecabtagene Autoleucel (eque-cel) is an autologous chimeric antigen receptor T-cell (CAR-T) therapy that targets B-cell maturation antigen (BCMA), which expressed on both mature B lymphocytes and malignant plasma cells. The primary objective for this study is to compare the efficacy of eque-cel versus standard therapy in lenalidomid-refractory RRMM. Subjects will undergo screening with informed consent. After enrollment, randomization will be conducted followed by study treatment in experimental or control group. A follow-up phase will include assessments for safety, efficacy evaluation and pharmacokinetics monitoring (experimental arm) . The duration of this trial is about 6 years.

Studientyp

Interventionell

Einschreibung (Geschätzt)

260

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Beijing, China
        • Peking University First Hospital
      • Beijing, China
        • Peking University Third Hospital
      • Beijing, China
        • Peking Union Medical College Hospital
      • Beijing, China
        • People's Hospital of Peking University
      • Beijing, China
        • Beijing Chao-Yang Hospital, Capital Medical University
      • Beijing, China
        • Beijing GoBoard Boren Hospital
      • Beijing, China
        • Fu Xing Hospital, Capital Medical University
      • Changchun, China
        • The first hospital of Jilin University
      • Chengdu, China
        • West China School of Medicine, West China Hospital of Sichuan University
      • Chongqing, China
        • Xinqiao Hospital of AMU
      • Guangzhou, China
        • Nanfang Hospital, Southern Medical University
      • Guangzhou, China
        • Sun Yat-sen University Cancer Centre
      • Guangzhou, China
        • Zhujiang Hospital of Southern Medical University Guangdong
      • Hangzhou, China
        • The First Affiliated Hospital, College of Medicine, Zhejiang University
      • Hangzhou, China
        • The Second Affiliated Hospital,Zhejiang University School of Medicine
      • Jinan, China
        • Qilu Hospital of Shangdong University
      • Nanchang, China
        • The First Affiliated Hospital of Nanchang University
      • Nanjing, China
        • Jiangsu Province Hospital
      • Nanjing, China
        • Affiliated Drum Tower Hospital, Medical School of Nanjing University
      • Ningbo, China
        • The Affiliated People's Hospital of Ningbo University
      • Shanghai, China
        • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
      • Suzhou, China
        • The First Affiliated Hospital of Soochow University
      • Tianjin, China
        • Tianjin Medical University General Hospital
      • Tianjin, China
        • Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
      • Wenzhou, China
        • The First Affiliated Hospital of Wenzhou Medical University
      • Wuhan, China
        • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
      • Wuhan, China
        • Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
      • Zhengzhou, China
        • Henan Cancer Hospital Affilated Cancer Hospital of Zhengzhou University
      • Fukuoka, Japan
        • Kyushu University Hospital
      • Hiroshima, Japan
        • Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital
      • Hokkaido, Japan
        • Hokkaido University Hospital
      • Hyōgo, Japan
        • Hyogo Medical University Hospital
      • Kyoto, Japan
        • University Hospital, Kyoto Prefectural University of Medicine
      • Nagoya, Japan
        • Nagoya City University Hospital
      • Osaka, Japan
        • Kindai University Hospital
      • Osaka, Japan
        • The University of Osaka Hospital
      • Tochigi, Japan
        • Jichi Medical University Hospital
      • Tokyo, Japan
        • Nihon University Itabashi Hospital
      • Tokyo, Japan
        • Tokyo Metropolitan Komagome Hospital
      • Tokyo, Japan
        • Japanese Red Cross Medical Center
      • Tokyo, Japan
        • Institute of Science Tokyo Hospital

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 75 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. 18 to 75 years of age (inclusive of critical values), either gender.
  2. The subject was previously diagnosed with multiple myeloma and had received 1-2 lines of therapy (including chemotherapy regimens based on proteasome inhibitors and immunomodulatory agents, with each line of therapy receiving at least 1 full cycle ; Documented disease progression during or within 12 months after the most recent anti-myeloma therapy.
  3. Subjects was lenalidomide-refractory during prior therapy.
  4. ECOG score of 0 or 1.
  5. Subjects must have appropriate organ function and meet all of the following laboratory test results before enrollment:

(1) Haematology: Absolute neutrophil count (ANC) ≥1×10^9/L (prior use of granulocyte colony-stimulating factor [G-CSF] support is permitted, but no supportive therapy have been received within 7 days before the laboratory test);Absolute lymphocyte count (ALC) ≥0.3×10^9/L; Platelets ≥50×10^9/L (must not have received platelet transfusion within 7 days prior to laboratory test); Hemoglobin ≥60g/L (must not have received red blood cells transfusion within 7 days prior to laboratory test); (2) Hepatic function: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 times of upper limit of normal (ULN); Serum total bilirubin ≤1.5 times of ULN; (3) Renal function: creatinine clearance (CrCl) calculated by Cockcroft-Gault formula ≥ 40 ml/min; (4) Coagulation: fibrinogen≥1.0 g/L; activated partial thromboplastin time (APTT) ≤ 1.5×ULN, pro-thrombin time (PT) ≤ 1.5 × ULN; (5) Pulse oxygen saturation > 91%; (6) Left ventricular ejection fraction (LVEF)≥50%;

6. Subjects agree to use effective tools or drug contraception (excluding safe period contraception) after signing the informed consent form.

7. Subjects must agree to sign or personally sign an ethics committee-approved informed consent form before starting any screening procedures.

Exclusion Criteria:

  1. Subjects who have used or required long-term immune-suppressive agents (e.g., cyclosporine or systemic steroids) within 14 days prior to enrollment, but the use of physiological substitutes, intermittent, topical, and inhaled steroids is allowed.
  2. Subjects who have undergone autologous haematopoietic stem cell transplantation (Auto-HSCT) within 12 weeks prior to randomization, or who have previously undergone allogeneic haematopoietic stem cell transplantation (Allo-HSCT).
  3. Subjects received the following anti-tumor treatments before enrollment: (1)Treated with an immunomodulator within 7 days, or; (2)Received plasma exchange, radiotherapy (except local radiotherapy for myeloma-related bone lesions), cytotoxic chemotherapy, treatment with proteasome inhibitors or other investigational drug within 14 days, or; (3) Treatment with monoclonal antibody for multiple myeloma within 21 days, or; (4) Received other anti-cancer therapy within 14 days or at least 5 half-lives (whichever is shorter) prior to enrollment.
  4. Significant cardiac disorder.
  5. Unstable systemic disease as judged by the investigator: including but not limited to severe liver, renal, or metabolic disease requiring medication.
  6. The subject will not be able to participate in this study if the investigator determines that the subject meets any of the following conditions: (1) Subjects with a history of allergic reaction to the excipient components (DMSO and albumin) of Eque-cel, fludarabine, cyclophosphamide, tocilizumab, or; (2) Subjects who are intolerant to dexamethasone, or; (3) Subjects who have a Life-threatening allergy, hypersensitivity reaction, or intolerance to pomalidomide and/or its excipients (intolerance is defined as discontinuation of prior treatment due to any AE related to pomalidomide) or;
  7. Have malignancies other than multiple myeloma within 5 years before screening, excluding cervical carcinoma in situ after radical surgery, basal cell or squamous cell skin cancer, localized cancer of prostate after radical prostatectomy, breast ductal carcinoma in situ after radical mastectomy or carcinoma papillary thyroid after radical thyroidectomy.
  8. Subjects suspected or confirmed to have central nervous system involvement of MM during the screening period.
  9. Subjects with concurrent plasma cell leukemia(defined as plasma cell proportion in peripheral blood > 5%), Waldenström macroglobulinaemia, POEMS syndrome (polyneuropathy, organ hypertrophy, endocrinopathy, monoclonal protein and skin changes) or primary amyloidosis during screening period.
  10. Patients with concomitant non-paraskeletal extramedullary soft tissue plasmacytoma (EM-E); patients with multiple paraskeletal extramedullary lesions (EM-B) where the longest diameter of the extramedullary part of any lesion is >3 cm; patients with a single paraskeletal extramedullary lesion (EMB) where the longest diameter of the extramedullary part is >5 cm;.
  11. Had major surgery within 2 weeks prior to randomization or planned to have surgery within 2 weeks after study treatment (except for subjects who were scheduled to have surgery under local anesthesia).
  12. Subject with uncontrollable infection.
  13. Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and hepatitis B virus (HBV) DNA quantification in peripheral blood was higher than the lower limit of detection; hepatitis C virus (HCV) antibody positive and hepatitis C virus (HCV) RNA positive in peripheral blood; Human immunodeficiency virus (HIV) antibody positive; Syphilis test positive; positive cytomegalovirus (CMV) DNA.
  14. Pregnant or breastfeeding women.
  15. The subject has a history of central nervous system disorder within 6 months prior to signing the informed consent form.
  16. Non-hematological toxicity reactions due to prior treatment have not resolved to baseline or ≤ Grade 1 (NCI-CTCAE v5.0, alopecia, Grade 2 peripheral neuropathy were excepted).
  17. Subjects had other conditions that the investigator considered unsuitable for enrollment.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Experimental group

Drug:Equecabtagene Autoleucel Injection

dosage form: injection, dosage: 1.0×10^6 CAR-T/kg, frequency: single dose.

Andere Namen:
  • FUCASO
Aktiver Komparator: Control group

Drug:

Daratumumab, Bortezomib, Dexamethasone, Pomalidomide, DPd group: Daratumumab, Pomalidomide, Dexamethasone PVd group: Bortezomib, Dexamethasone, Pomalidomide

dosage form: injection or subcutaneous injection. For intravenous administration: dose level 16 mg/kg, 28 days/cycle for the DPd regimen

  • Cycle1-2: D1, D8, D15, D22;
  • Cycle3-6: D1, D15;
  • above Cycle7: D1; body weight should be recalculated on D1 of the current cycle if it differs from baseline by more than +/-10%.

For subcutaneous administration: fixed dose of 1,800 mg. The formulation and route of administration (intravenous or subcutaneous) should be selected according to the clinical practice in the country where the study is conducted.

dosage form:capsule. doseage form: capsule. dose level: 4mg/d. frequency: every cycle: D1-D21 for DPd regimen, D1-D14 for PVd regimen.

dosage form: subcutaneous injection. dose level: 1.3mg/m2. frequency: 21days/cycle for PVd regimen cycle 1-8: D1,D4, D8, D11; above cycle 9: D1, D8.

dosage form: oral or intravenus injection. dose level:20mg/d. frequency: for DPd: every cycle, D1, D2, D8, D9, D15, D16, D22, D23; for PVd: Cycle1-8:D1, D2, D4, D5, D8, D9, D11, D12; above Cycle 9: D1, D2, D8, D9.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Minimal Residual Disease (MRD)-negative complete response (CR) rate at 12 months
Zeitfenster: 12 months (+/-3 months) post-randomization

The proportion of the first 126 randomized subjects who achieved a complete response (CR) or better, as assessed by Independent Review Committee (IRC), and were MRD-negative (assessed by next-generation flow cytometry [NGF] using the EuroFlow standard operating procedure) at 12 months (+/-3 months) post-randomization.

12 months (+/-3 months) post-randomization
Progression-Free Survival (PFS) as assessed by Independent Review Committee (IRC)
Zeitfenster: up to 5 years from randomization

The time from randomization to the first IRC-assessed disease progression or death from any cause.

up to 5 years from randomization

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Overall MRD negativity rate
Zeitfenster: up to 5 years from randomization

The proportion of subjects who achieve MRD negativity at any time after the date of randomization and before the initiation of subsequent therapy

up to 5 years from randomization
Duration of MRD negativity
Zeitfenster: up to 5 years from randomization

The time from first achievement of MRD negativity to the first subsequent positive MRD status

up to 5 years from randomization
Complete Response Rate(CRR)
Zeitfenster: up to 5 years from randomization

The proportion of subjects who achieve CR or better post-randomization among all randomized subjects

up to 5 years from randomization
Very good partial response or better response (≥VGPR) rate
Zeitfenster: up to 5 years from randomization

The proportion of subjects who achieve sCR, CR, or VGPR post-randomization among all randomized subjects

up to 5 years from randomization
Overall Response Rate(ORR)
Zeitfenster: up to 5 years from randomization

The proportion of subjects who achieve sCR, CR, VGPR, or PR post-randomization among all randomized subjects.

up to 5 years from randomization
Duration of Response (DOR)
Zeitfenster: up to 5 years from randomization

The time from the first date of initial documented response (≥PR) to the date of first disease progression or death from any cause, whichever occurs first, post-randomization

up to 5 years from randomization
Event-Free Survival (EFS)
Zeitfenster: up to 5 years from randomization

Time from randomization to the first occurrence of any of the following events: death, disease progression, initiation of a new anti-myeloma therapy, addition of other treatments, or occurrence of fatal or intolerable adverse effects

up to 5 years from randomization
Overall Survival(OS)
Zeitfenster: up to 5 years from randomization

Defined as the time from randomization to death due to any cause

up to 5 years from randomization
Time to Next Treatment(TTNT)
Zeitfenster: up to 5 years from randomization

Time from randomization to the initiation of a new subsequent anti-myeloma therapies

up to 5 years from randomization
Incidence of Adverse events
Zeitfenster: up to 5 years from randomization

Safety Endpoint

up to 5 years from randomization
Pharmacokinetic Endpoint-Cmax
Zeitfenster: up to 5 years from Eque-cel infusion

The maximum concentration (Cmax) of CAR VCN and BCMA CAR-T in peripheral blood after CAR-T infusion

up to 5 years from Eque-cel infusion
Pharmacokinetic Endpoint-Tmax
Zeitfenster: up to 5 years from Eque-cel infusion

the time for CAR VCN and BCMA CAR-T to reach the maximum concentration (Tmax) after CAR-T infusion

up to 5 years from Eque-cel infusion
Pharmacokinetic Endpoint-AUC
Zeitfenster: up to 5 years from Eque-cel infusion

Area under the curve of 29, 85, 169 days and the last time point of PK detection (AUC0-29d, AUC0-85d, AUC0-169d, AUC0-last) for CAR VCN; Area under the curve of 29 days (AUC0-29) for BCMA CAR-T.

up to 5 years from Eque-cel infusion
Pharmacodynamic Endpoint
Zeitfenster: up to 5 years from Eque-cel infusion

The concentration of soluble BCMA in peripheral blood of experimental group at each time point

up to 5 years from Eque-cel infusion
Health Related Quality of Life Endpoint
Zeitfenster: up to 5 years from randomization

Symptoms, function, and overall HRQoL were collected using the validated Patient-Reported Outcomes (PRO) questionnaire

up to 5 years from randomization

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Gui Lu Qiu, PhD, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
  • Hauptermittler: Zhen Cai, PhD, First Affiliated Hospital of Zhejiang University

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

27. März 2024

Primärer Abschluss (Geschätzt)

1. August 2027

Studienabschluss (Geschätzt)

1. Dezember 2030

Studienanmeldedaten

Zuerst eingereicht

30. Mai 2024

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

17. Juni 2024

Zuerst gepostet (Tatsächlich)

18. Juni 2024

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

6. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

3. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .